Patents by Inventor Joshua David FREEDMAN

Joshua David FREEDMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenovirus armed with bispecific T cell engager
    Patent number: 12258417
    Abstract: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with at least two bispecific T cell engagers each comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on an immune cell of interest, such as a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: March 25, 2025
    Assignee: AKAMIS BIO LIMITED
    Inventors: Brian Robert Champion, Alice Claire Noel Bromley, Joshua David Freedman, Kerry David Fisher, Leonard William Seymour
  • ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR
    Publication number: 20250026851
    Abstract: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell activator comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
    Type: Application
    Filed: June 14, 2024
    Publication date: January 23, 2025
    Inventors: Brian Robert CHAMPION, Alice Claire Noel BROMLEY, Joshua David FREEDMAN, Kerry David FISHER, Leonard William SEYMOUR
  • Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
    Patent number: 12049513
    Abstract: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell activator comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: July 30, 2024
    Assignee: AKAMIS BIO LIMITED
    Inventors: Brian Robert Champion, Alice Claire Noel Bromley, Joshua David Freedman, Kerry David Fisher, Leonard William Seymour
  • ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)
    Publication number: 20190233536
    Abstract: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with at least two bispecific T cell engager (BiTE™) each comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on an immune cell of interest, such as a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
    Type: Application
    Filed: August 29, 2017
    Publication date: August 1, 2019
    Inventors: Brian Robert CHAMPION, Alice Claire Noel BROMLEY, Joshua David FREEDMAN, Kerry David FISHER, Leonard William SEYMOUR
  • ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)
    Publication number: 20190194690
    Abstract: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell engager (BiTE™) comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
    Type: Application
    Filed: August 29, 2017
    Publication date: June 27, 2019
    Inventors: Brian Robert CHAMPION, Alice Claire Noel BROMLEY, Joshua David FREEDMAN, Kerry David FISHER, Leonard William SEYMOUR